Table 2 Cox-regression analysis of risk factors
From: How to manage synchronous endometrial and ovarian cancer patients?
Variables | Overall survival | Recurrence-free survival | ||||
|---|---|---|---|---|---|---|
N (event) | HR (95% CI) | P-value | N (event) | HR (95% CI) | P-value | |
Age | 47 (4) | 1.05 (0.93–1.18) | 0.428 | 47 (12) | 1.05 (0.98–1.11) | 0.173 |
Pelvic_LN_pathology | ||||||
No | 41 (3) | 1 | 41 (9) | 1 | ||
Yes | 6 (1) | 3.57 (0.36–35.05) | 0.275 | 6 (3) | 3.86 (0.96–15.46) | 0.057 |
paraaortic_LN | ||||||
No | 42 (3) | 1 | 42 (9) | 1 | ||
Yes | 5 (1) | 3.80 (0.39–36.90) | 0.250 | 5 (3) | 4.84 (1.21–19.41) | 0.026 |
LVS | ||||||
No | 40 (3) | 1 | 40 (11) | 1 | ||
Yes | 7 (1) | 2.29 (0.24–22.13) | 0.474 | 7 (1) | 0.54 (0.07–4.18) | 0.554 |
Endocervix-invasion | ||||||
No | 42 (4) | 1 | 42 (11) | 1 | ||
Yes | 5 (0) | 5 (1) | 0.60 (0.08–4.64) | 0.623 | ||
Pelvic peritoneum invasion | ||||||
No | 36 (2) | 1 | 36 (8) | 1 | ||
Yes | 11 (2) | 3.17 (0.44–22.96) | 0.253 | 11 (4) | 1.63 (0.49–5.41) | 0.427 |
Stage_EM | ||||||
1 + 2 | 32 (2) | 1 | 32 (9) | 1 | ||
3 + 4 | 15 (2) | 2.60 (0.36–18.54) | 0.342 | 15 (3) | 0.71 (0.19–2.63) | 0.610 |
Stage_OV | ||||||
1 + 2 | 27 (0) | 1 | 27 (3) | 1 | ||
3 + 4 | 8 (2) | 8 (6) | 12.16 (2.87–51.59) | 0.001 | ||
Histology_EM | ||||||
Non-endometrioid | 11 (3) | 1 | 11 (7) | 1 | ||
Endometrioid | 36 (1) | 0.09 (0.01–0.84) | 0.035 | 36 (5) | 0.15 (0.05–0.49) | 0.002 |
Histology_OV | ||||||
Non-endometrioid | 22 (4) | 1 | 22 (9) | 1 | ||
Endometrioid | 25 (0) | 25 (3) | 0.20 (0.05–0.73) | 0.016 | ||
Grade_EM | ||||||
1 | 17 (1) | 1 | 17 (3) | 1 | ||
2 + 3 | 22 (1) | 0.81 (0.05–13.01) | 0.884 | 22 (2) | 0.59 (0.1–3.55) | 0.567 |
Grade_OV | ||||||
1 | 15 (1) | 1 | 15 (4) | 1 | ||
2 + 3 | 25 (2) | 1.22 (0.11–13.45) | 0.873 | 25 (5) | 0.84 (0.23–3.14) | 0.798 |
Adjuvant CTx | ||||||
No | 7 (1) | 1 | 7 (1) | 1 | ||
Yes | 40 (3) | 0.47 (0.05–4.54) | 0.516 | 40 (11) | 1.95 (0.25–15.16) | 0.521 |
Adjuvant RTx | ||||||
No | 42 (4) | 1 | 42 (10) | 1 | ||
Yes | 5 (0) | 5 (2) | 1.35 (0.30–6.17) | 0.700 | ||